Category - Developments

Developments

FDA fast tracks BioRestorative’s BRTX-100 in cLDD

BioRestorative Therapies (NASDAQ:BRTX) has announced that the FDA has granted Fast Track designation to the BRTX-100 stem cell program for the treatment of chronic lumbar disc disease (cLDD). “We are thrilled that the...

February 20, 2025

Developments

MOBILion showcases new mass spectrometry approach at US HUPO conference

Closely held MOBILion Systems has announced its participation in the 21st annual US HUPO conference this month in Philadelphia. The company will showcase its new Parallel Accumulation with Mobility Aligned Fragmentation...

February 19, 2025

Developments

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

Non-profit Allegheny Health Network (AHN) has introduced the groundbreaking EksoNR, a wearable, full-body robotic exoskeleton that assists patients recovering from neurological injury or disease. The weight-bearing...

February 19, 2025

Developments

First New Mexico Hospital leverages Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V:Pink; OTC:PYNKF) announced that CHRISTIS St. Vincent is the first hospital in New Mexico to use its optical coherence technology (OCT), S-Series OCT, to visualize tissue margins...

February 19, 2025

Developments

Theratechnologies resumes U.S. supply of EGRIFTA SV for HIV

Theratechnologies (TSX:TH; NASDAQ:THTX) announced that the FDA has granted approval for the company to resume U.S. distribution of its tesamorelin injection, EGRIFTA SV, for patients with HIV. According to the company...

February 14, 2025

Developments

Medicus provides update on Phase 2 study of D-MNA in BCC

Medicus Pharma (NASDAQ:MDCX) announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of...

February 14, 2025

Developments

Pliant assembles expert panel to review bexotegrast trial data in IPF

Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review...

February 13, 2025

Developments

Top-tier journal publishes NKGen’s trial results on troculeucel in AD

NKGen Biotech (NASDAQ:NKGN) announced that results from its initial dose-escalation Phase 1 trial of troculeucel for the treatment of Alzheimer’s disease (AD) have been published in the international, peer-reviewed...

February 13, 2025

Developments

Top-tier journal describes unique properties of Aclaris’ ATI-2138

Aclaris Therapeutics (NASDAQ:ACRS) has announced that a publication in The Journal of Pharmacology and Experimental Therapeutics describes the unique properties its investigational drug, ATI-2138, which is in...

February 12, 2025

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Category - Developments

Subscribe